Sygnature Discovery’s hit finding expertise in high demand as cardiac biotech customer, River BioMedics, receives an additional €2M seed investment

Sygnature Discovery is delighted to announce that its customer, River BioMedics, has raised an additional €2M in seed funding to continue its life-saving cardiovascular drug research.

Libertatis Ergo Holding, an independent subsidiary of Leiden University joins the investment syndicate alongside further investment from existing investors FIRST fund, managed by BioGeneration Ventures (BGV), KIKK Capital and Oost NL.

The biotech will continue partnering with Sygnature to drive its novel, genetically validated cardiovascular disease project pipeline.

River BioMedics will partner with Sygnature Discovery to drive its novel, genetically validated cardiovascular drug research project pipeline

The two companies have collaborated in cardiovascular drug discovery since March 2021. Programs have integrated Sygnature’s novel assay development and hit identification expertise with River BioMedics’ unique, state-of-the-art technology to advance human-predictive in vitro 3D heart models and its deep knowledge of cardiac biology.

The biotech’s aim is to develop medicines that treat the underlying cause of heart failure rather than merely treating the symptoms. The new investment sees River BioMedics and Sygnature Discovery further strengthen their successful partnership through continued cardiovascular drug research and collaboration.

River BioMedics says it will utilise the funds to advance compound development for its lead project, which is focused on heart failure with preserved ejection fraction, and to continue efforts on its earlier-stage pipeline.

John Unitt, Vice President of Inflammation and Immunology at Sygnature Discovery, says:

“It’s great that River BioMedics has attracted further funding to support its ongoing cardiovascular drug research and will continue to collaborate with Sygnature to progress its projects.”

Nicky Cooper, CEO at River BioMedics, says:

“We are excited to have this additional funding to enable us to continue to collaborate with the highly experienced Sygnature scientists on our drug discovery programs for cardiovascular disease.”

Work continues between the two companies across a number of cardiovascular-related projects.

About Sygnature Discovery

Sygnature Discovery is a world-leading integrated drug discovery Contract Research Organization based in the UK and Canada with headquarters in Nottingham (UK). Additional sites are located in Alderley Park, Macclesfield, Glasgow, Montreal and Quebec City. Its team of over 1,000 employees, which includes 900 scientists, partners with global pharma, biotech and NFP organisations. Since 2004, Sygnature Discovery has delivered over 40 novel pre-clinical and 22 clinical compounds, with its scientists named on over 170 patents. Therapeutic areas of expertise include oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, fibrotic diseases and more.

For further information, visit


About River BioMedics

River BioMedics, is a cardiovascular drug discovery company focused on integrating in-house, cutting-edge bio-engineering technologies, with novel cardiac biology and drug discovery expertise to develop life-transforming medicines for cardiovascular disease. The company is building a portfolio of disease modifying small molecule drugs, against genetically validated, cardiac targets with an initial focus on heart failure with preserved ejection fraction (HFpEF), an area of high unmet medical need. The company’s 3D cardiac strip platform has applicability across all heart diseases and provides in-vitro human PoC early in the discovery process, aiming to enhance pre-clinical to clinical efficacy translation.

For further information, visit

Latest News

View All

Sygnature Discovery Receives EcoVadis Award For Sustainable…

Sygnature Discovery goes for global industry recognition…

First patients dosed in Phase 1a clinical…

Sygnature Discovery Appoints Industry Leaders To Board…